Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma

Pediatric patients with relapsed or refractory rhabdomyosarcoma (RMS) have dismal cure rates, and effective therapy is urgently needed. The oncogenic receptor tyrosine kinase fibroblast growth factor receptor 4 (FGFR4) is highly expressed in RMS and lowly expressed in healthy tissues. Here, we descr...

Full description

Saved in:
Bibliographic Details
Published inCell reports. Medicine Vol. 4; no. 10; p. 101212
Main Authors Tian, Meijie, Wei, Jun S., Shivaprasad, Nityashree, Highfill, Steven L., Gryder, Berkley E., Milewski, David, Brown, G. Tom, Moses, Larry, Song, Hannah, Wu, Jerry T., Azorsa, Peter, Kumar, Jeetendra, Schneider, Dina, Chou, Hsien-Chao, Song, Young K., Rahmy, Abdelrahman, Masih, Katherine E., Kim, Yong Yean, Belyea, Brian, Linardic, Corinne M., Dropulic, Boro, Sullivan, Peter M., Sorensen, Poul H., Dimitrov, Dimiter S., Maris, John M., Mackall, Crystal L., Orentas, Rimas J., Cheuk, Adam T., Khan, Javed
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 17.10.2023
Elsevier
Subjects
Advanced Basic Science
Animals
CAR T cell therapy
Cell Line, Tumor
Child
FGFR4
Humans
Immunotherapy, Adoptive
Mice
Receptor, Fibroblast Growth Factor, Type 4 - genetics
Receptor, Fibroblast Growth Factor, Type 4 - metabolism
Receptors, Chimeric Antigen - genetics
rhabdomyosarcoma
Rhabdomyosarcoma - drug therapy
specific cytotoxicity
specific cytotoxicity
rhabdomyosarcoma
FGFR4
CAR T cell therapy
Online AccessGet full text

Cover

Abstract Pediatric patients with relapsed or refractory rhabdomyosarcoma (RMS) have dismal cure rates, and effective therapy is urgently needed. The oncogenic receptor tyrosine kinase fibroblast growth factor receptor 4 (FGFR4) is highly expressed in RMS and lowly expressed in healthy tissues. Here, we describe a second-generation FGFR4-targeting chimeric antigen receptor (CAR), based on an anti-human FGFR4-specific murine monoclonal antibody 3A11, as an adoptive T cell treatment for RMS. The 3A11 CAR T cells induced robust cytokine production and cytotoxicity against RMS cell lines in vitro. In contrast, a panel of healthy human primary cells failed to activate 3A11 CAR T cells, confirming the selectivity of 3A11 CAR T cells against tumors with high FGFR4 expression. Finally, we demonstrate that 3A11 CAR T cells are persistent in vivo and can effectively eliminate RMS tumors in two metastatic and two orthotopic models. Therefore, our study credentials CAR T cell therapy targeting FGFR4 to treat patients with RMS. [Display omitted] •FGFR4 is highly expressed in rhabdomyosarcoma and lowly expressed in healthy human tissue•FGFR4 is a downstream target of the PAX3-FOXO1 fusion oncogene•FGFR4 CAR T cells demonstrate no cytokine release against primary human cells•FGFR4 CAR T cells eliminate metastatic and intramuscular solid RMS tumors in vivo Tian et al. develop a potent clinical-grade CAR targeting FGFR4 that is highly expressed in rhabdomyosarcoma. FGFR4 CAR T cells show specific cytotoxicity against RMS cell lines and are non-reactive to healthy human primary cells. These CAR T cells eliminate tumors in metastatic and orthotopic mouse models of RMS.
AbstractList Pediatric patients with relapsed or refractory rhabdomyosarcoma (RMS) have dismal cure rates, and effective therapy is urgently needed. The oncogenic receptor tyrosine kinase fibroblast growth factor receptor 4 (FGFR4) is highly expressed in RMS and lowly expressed in healthy tissues. Here, we describe a second-generation FGFR4-targeting chimeric antigen receptor (CAR), based on an anti-human FGFR4-specific murine monoclonal antibody 3A11, as an adoptive T cell treatment for RMS. The 3A11 CAR T cells induced robust cytokine production and cytotoxicity against RMS cell lines in vitro. In contrast, a panel of healthy human primary cells failed to activate 3A11 CAR T cells, confirming the selectivity of 3A11 CAR T cells against tumors with high FGFR4 expression. Finally, we demonstrate that 3A11 CAR T cells are persistent in vivo and can effectively eliminate RMS tumors in two metastatic and two orthotopic models. Therefore, our study credentials CAR T cell therapy targeting FGFR4 to treat patients with RMS. [Display omitted] •FGFR4 is highly expressed in rhabdomyosarcoma and lowly expressed in healthy human tissue•FGFR4 is a downstream target of the PAX3-FOXO1 fusion oncogene•FGFR4 CAR T cells demonstrate no cytokine release against primary human cells•FGFR4 CAR T cells eliminate metastatic and intramuscular solid RMS tumors in vivo Tian et al. develop a potent clinical-grade CAR targeting FGFR4 that is highly expressed in rhabdomyosarcoma. FGFR4 CAR T cells show specific cytotoxicity against RMS cell lines and are non-reactive to healthy human primary cells. These CAR T cells eliminate tumors in metastatic and orthotopic mouse models of RMS.
Pediatric patients with relapsed or refractory rhabdomyosarcoma (RMS) have dismal cure rates, and effective therapy is urgently needed. The oncogenic receptor tyrosine kinase fibroblast growth factor receptor 4 (FGFR4) is highly expressed in RMS and lowly expressed in healthy tissues. Here, we describe a second-generation FGFR4-targeting chimeric antigen receptor (CAR), based on an anti-human FGFR4-specific murine monoclonal antibody 3A11, as an adoptive T cell treatment for RMS. The 3A11 CAR T cells induced robust cytokine production and cytotoxicity against RMS cell lines in vitro. In contrast, a panel of healthy human primary cells failed to activate 3A11 CAR T cells, confirming the selectivity of 3A11 CAR T cells against tumors with high FGFR4 expression. Finally, we demonstrate that 3A11 CAR T cells are persistent in vivo and can effectively eliminate RMS tumors in two metastatic and two orthotopic models. Therefore, our study credentials CAR T cell therapy targeting FGFR4 to treat patients with RMS.
SummaryPediatric patients with relapsed or refractory rhabdomyosarcoma (RMS) have dismal cure rates, and effective therapy is urgently needed. The oncogenic receptor tyrosine kinase fibroblast growth factor receptor 4 ( FGFR4) is highly expressed in RMS and lowly expressed in healthy tissues. Here, we describe a second-generation FGFR4-targeting chimeric antigen receptor (CAR), based on an anti-human FGFR4-specific murine monoclonal antibody 3A11, as an adoptive T cell treatment for RMS. The 3A11 CAR T cells induced robust cytokine production and cytotoxicity against RMS cell lines in vitro. In contrast, a panel of healthy human primary cells failed to activate 3A11 CAR T cells, confirming the selectivity of 3A11 CAR T cells against tumors with high FGFR4 expression. Finally, we demonstrate that 3A11 CAR T cells are persistent in vivo and can effectively eliminate RMS tumors in two metastatic and two orthotopic models. Therefore, our study credentials CAR T cell therapy targeting FGFR4 to treat patients with RMS.
Pediatric patients with relapsed or refractory rhabdomyosarcoma (RMS) have dismal cure rates, and effective therapy is urgently needed. The oncogenic receptor tyrosine kinase fibroblast growth factor receptor 4 (FGFR4) is highly expressed in RMS and lowly expressed in healthy tissues. Here, we describe a second-generation FGFR4-targeting chimeric antigen receptor (CAR), based on an anti-human FGFR4-specific murine monoclonal antibody 3A11, as an adoptive T cell treatment for RMS. The 3A11 CAR T cells induced robust cytokine production and cytotoxicity against RMS cell lines in vitro. In contrast, a panel of healthy human primary cells failed to activate 3A11 CAR T cells, confirming the selectivity of 3A11 CAR T cells against tumors with high FGFR4 expression. Finally, we demonstrate that 3A11 CAR T cells are persistent in vivo and can effectively eliminate RMS tumors in two metastatic and two orthotopic models. Therefore, our study credentials CAR T cell therapy targeting FGFR4 to treat patients with RMS.Pediatric patients with relapsed or refractory rhabdomyosarcoma (RMS) have dismal cure rates, and effective therapy is urgently needed. The oncogenic receptor tyrosine kinase fibroblast growth factor receptor 4 (FGFR4) is highly expressed in RMS and lowly expressed in healthy tissues. Here, we describe a second-generation FGFR4-targeting chimeric antigen receptor (CAR), based on an anti-human FGFR4-specific murine monoclonal antibody 3A11, as an adoptive T cell treatment for RMS. The 3A11 CAR T cells induced robust cytokine production and cytotoxicity against RMS cell lines in vitro. In contrast, a panel of healthy human primary cells failed to activate 3A11 CAR T cells, confirming the selectivity of 3A11 CAR T cells against tumors with high FGFR4 expression. Finally, we demonstrate that 3A11 CAR T cells are persistent in vivo and can effectively eliminate RMS tumors in two metastatic and two orthotopic models. Therefore, our study credentials CAR T cell therapy targeting FGFR4 to treat patients with RMS.
Pediatric patients with relapsed or refractory rhabdomyosarcoma (RMS) have dismal cure rates, and effective therapy is urgently needed. The oncogenic receptor tyrosine kinase fibroblast growth factor receptor 4 ( FGFR4 ) is highly expressed in RMS and lowly expressed in healthy tissues. Here, we describe a second-generation FGFR4-targeting chimeric antigen receptor (CAR), based on an anti-human FGFR4-specific murine monoclonal antibody 3A11, as an adoptive T cell treatment for RMS. The 3A11 CAR T cells induced robust cytokine production and cytotoxicity against RMS cell lines in vitro . In contrast, a panel of healthy human primary cells failed to activate 3A11 CAR T cells, confirming the selectivity of 3A11 CAR T cells against tumors with high FGFR4 expression. Finally, we demonstrate that 3A11 CAR T cells are persistent in vivo and can effectively eliminate RMS tumors in two metastatic and two orthotopic models. Therefore, our study credentials CAR T cell therapy targeting FGFR4 to treat patients with RMS. • FGFR4 is highly expressed in rhabdomyosarcoma and lowly expressed in healthy human tissue • FGFR4 is a downstream target of the PAX3-FOXO1 fusion oncogene • FGFR4 CAR T cells demonstrate no cytokine release against primary human cells • FGFR4 CAR T cells eliminate metastatic and intramuscular solid RMS tumors in vivo Tian et al. develop a potent clinical-grade CAR targeting FGFR4 that is highly expressed in rhabdomyosarcoma. FGFR4 CAR T cells show specific cytotoxicity against RMS cell lines and are non-reactive to healthy human primary cells. These CAR T cells eliminate tumors in metastatic and orthotopic mouse models of RMS.
ArticleNumber 101212
Author Belyea, Brian
Kim, Yong Yean
Dimitrov, Dimiter S.
Sorensen, Poul H.
Highfill, Steven L.
Shivaprasad, Nityashree
Rahmy, Abdelrahman
Song, Hannah
Sullivan, Peter M.
Moses, Larry
Tian, Meijie
Linardic, Corinne M.
Gryder, Berkley E.
Schneider, Dina
Kumar, Jeetendra
Wu, Jerry T.
Song, Young K.
Masih, Katherine E.
Wei, Jun S.
Brown, G. Tom
Azorsa, Peter
Khan, Javed
Mackall, Crystal L.
Maris, John M.
Chou, Hsien-Chao
Orentas, Rimas J.
Dropulic, Boro
Milewski, David
Cheuk, Adam T.
Author_xml – sequence: 1
  givenname: Meijie
  surname: Tian
  fullname: Tian, Meijie
  organization: Genetics Branch, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Bethesda, MD 20892, USA
– sequence: 2
  givenname: Jun S.
  surname: Wei
  fullname: Wei, Jun S.
  organization: Genetics Branch, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Bethesda, MD 20892, USA
– sequence: 3
  givenname: Nityashree
  surname: Shivaprasad
  fullname: Shivaprasad, Nityashree
  organization: Genetics Branch, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Bethesda, MD 20892, USA
– sequence: 4
  givenname: Steven L.
  surname: Highfill
  fullname: Highfill, Steven L.
  organization: Center for Cellular Engineering, Department of Transfusion Medicine, National Institutes of Health Clinical Center, Bethesda, MD 20892, USA
– sequence: 5
  givenname: Berkley E.
  surname: Gryder
  fullname: Gryder, Berkley E.
  organization: Genetics Branch, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Bethesda, MD 20892, USA
– sequence: 6
  givenname: David
  surname: Milewski
  fullname: Milewski, David
  organization: Genetics Branch, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Bethesda, MD 20892, USA
– sequence: 7
  givenname: G. Tom
  surname: Brown
  fullname: Brown, G. Tom
  organization: Artificial Intelligence Resource, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA
– sequence: 8
  givenname: Larry
  surname: Moses
  fullname: Moses, Larry
  organization: Center for Cellular Engineering, Department of Transfusion Medicine, National Institutes of Health Clinical Center, Bethesda, MD 20892, USA
– sequence: 9
  givenname: Hannah
  surname: Song
  fullname: Song, Hannah
  organization: Center for Cellular Engineering, Department of Transfusion Medicine, National Institutes of Health Clinical Center, Bethesda, MD 20892, USA
– sequence: 10
  givenname: Jerry T.
  surname: Wu
  fullname: Wu, Jerry T.
  organization: Genetics Branch, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Bethesda, MD 20892, USA
– sequence: 11
  givenname: Peter
  surname: Azorsa
  fullname: Azorsa, Peter
  organization: Genetics Branch, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Bethesda, MD 20892, USA
– sequence: 12
  givenname: Jeetendra
  surname: Kumar
  fullname: Kumar, Jeetendra
  organization: Genetics Branch, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Bethesda, MD 20892, USA
– sequence: 13
  givenname: Dina
  surname: Schneider
  fullname: Schneider, Dina
  organization: Lentigen Corporation, Miltenyi Bioindustry, 1201 Clopper Road, Gaithersburg, MD 20878, USA
– sequence: 14
  givenname: Hsien-Chao
  surname: Chou
  fullname: Chou, Hsien-Chao
  organization: Genetics Branch, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Bethesda, MD 20892, USA
– sequence: 15
  givenname: Young K.
  surname: Song
  fullname: Song, Young K.
  organization: Genetics Branch, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Bethesda, MD 20892, USA
– sequence: 16
  givenname: Abdelrahman
  surname: Rahmy
  fullname: Rahmy, Abdelrahman
  organization: Genetics Branch, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Bethesda, MD 20892, USA
– sequence: 17
  givenname: Katherine E.
  surname: Masih
  fullname: Masih, Katherine E.
  organization: Genetics Branch, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Bethesda, MD 20892, USA
– sequence: 18
  givenname: Yong Yean
  surname: Kim
  fullname: Kim, Yong Yean
  organization: Genetics Branch, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Bethesda, MD 20892, USA
– sequence: 19
  givenname: Brian
  surname: Belyea
  fullname: Belyea, Brian
  organization: Department of Pediatrics, Duke University School of Medicine, Durham, NC 27710, USA
– sequence: 20
  givenname: Corinne M.
  surname: Linardic
  fullname: Linardic, Corinne M.
  organization: Department of Pediatrics, Duke University School of Medicine, Durham, NC 27710, USA
– sequence: 21
  givenname: Boro
  surname: Dropulic
  fullname: Dropulic, Boro
  organization: Caring Cross, 708 Quince Orchard Road, Gaithersburg, MD 20878, USA
– sequence: 22
  givenname: Peter M.
  surname: Sullivan
  fullname: Sullivan, Peter M.
  organization: Ben Towne Center for Childhood Cancer Research, Seattle Children’s Research Institute, 1100 Olive Way, Seattle, WA 98101, USA
– sequence: 23
  givenname: Poul H.
  surname: Sorensen
  fullname: Sorensen, Poul H.
  organization: Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC V5Z 1L3, Canada
– sequence: 24
  givenname: Dimiter S.
  surname: Dimitrov
  fullname: Dimitrov, Dimiter S.
  organization: University of Pittsburgh Department of Medicine, Pittsburgh, PA 15261, USA
– sequence: 25
  givenname: John M.
  surname: Maris
  fullname: Maris, John M.
  organization: Children’s Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
– sequence: 26
  givenname: Crystal L.
  surname: Mackall
  fullname: Mackall, Crystal L.
  organization: Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA
– sequence: 27
  givenname: Rimas J.
  surname: Orentas
  fullname: Orentas, Rimas J.
  organization: Ben Towne Center for Childhood Cancer Research, Seattle Children’s Research Institute, 1100 Olive Way, Seattle, WA 98101, USA
– sequence: 28
  givenname: Adam T.
  surname: Cheuk
  fullname: Cheuk, Adam T.
  email: cheukt@gmail.com
  organization: Genetics Branch, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Bethesda, MD 20892, USA
– sequence: 29
  givenname: Javed
  orcidid: 0000-0002-5858-0488
  surname: Khan
  fullname: Khan, Javed
  email: khanjav@mail.nih.gov
  organization: Genetics Branch, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Bethesda, MD 20892, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37774704$$D View this record in MEDLINE/PubMed
BookMark eNqFUstuEzEUtVARLaU_wAJ5ySbBj3kZIRCqSEGqBIKytjz2ncTDjB1sJyJ_02_pl-FRGlQqURaWX-ehe899io6cd4DQc0rmlNDqVT__pcM4Z4Tx6YFR9gidsKqqZrwW9OjO-RidxdgTQlhJacPJE3TM67oualKcoP5LAD1YZ7UasIEtDH49gkvYd1hhvbIjBKuxcskuweEMhnXyAV_dXGsYBpxWENR6h5MKS0jWLfHiYvG1wDZjV6o1ftz5qIL2o3qGHndqiHB2u5-i74sPV-cfZ5efLz6dv7-c6bJiacZp2zJCVSkUF11btVWtwUDBODGF4MIoI_JVmLYrTEMVq7WA0ijRCEqN4fwUvdvrrjftCEbnaoIa5DrYUYWd9MrKv3-cXcml30pKSpFXlRVe3ioE_3MDMcnRxqlc5cBvomRNTYRgrK4z9MVdsz8uhw5nQLMH6OBjDNBJbZNK1k_edsimcspT9nLKU055yn2emcruUQ_qD5Le7EmQW7y1EGTUFlxuoc3hJWm8fZj-9h79MB0_YAex95vgcniSysgkkd-mKZuGLKdD8t5kgdf_Fvif-284bORu
CitedBy_id crossref_primary_10_1002_med_22059
crossref_primary_10_1016_j_jcyt_2024_03_003
crossref_primary_10_1242_dmm_050704
crossref_primary_10_1038_s41467_024_50251_x
crossref_primary_10_3389_fimmu_2025_1485817
crossref_primary_10_1038_s41417_024_00823_2
crossref_primary_10_1038_s41571_024_00869_z
crossref_primary_10_1371_journal_pone_0310100
crossref_primary_10_1186_s40164_024_00564_w
Cites_doi 10.1615/CritRevOncog.2015013800
10.1158/1078-0432.CCR-10-3063
10.1002/onco.13859
10.1016/S0140-6736(14)61403-3
10.1158/2159-8290.CD-15-0583
10.1200/JCO.2007.14.7207
10.1038/s41586-022-04489-4
10.1158/1078-0432.CCR-18-2743
10.1074/jbc.M507440200
10.1016/j.ccell.2017.03.002
10.1126/science.aar6711
10.1016/j.ejca.2009.08.019
10.1097/00043426-200106000-00007
10.1038/s41388-022-02342-6
10.1056/NEJMoa1215134
10.1016/j.isci.2020.101103
10.1038/s41572-018-0051-2
10.1200/JCO.19.00576
10.1158/1535-7163.MCT-22-0059
10.1002/dvdy.10457
10.1158/2159-8290.CD-16-1297
10.1158/1078-0432.CCR-21-3803
10.1038/89044
10.1158/1078-0432.CCR-18-0432
10.1158/1078-0432.CCR-15-2717
10.1126/scitranslmed.aan4470
10.1158/2159-8290.CD-12-0548
10.1016/j.ccell.2021.12.005
10.1200/JCO.2015.63.4048
10.1158/2159-8290.CD-19-0945
10.1016/j.ccr.2013.11.002
10.1126/scitranslmed.aaa4963
10.1038/s41588-019-0534-4
10.1126/scitranslmed.abd6169
10.3390/cancers12113313
10.1186/bcr3674
10.1158/1078-0432.CCR-11-2056
10.1073/pnas.96.23.13264
10.1016/j.jviromet.2008.11.021
10.1172/JCI155621
10.1158/1078-0432.CCR-18-2035
10.1158/2159-8290.CD-13-0639
10.1016/j.ymthe.2017.06.008
10.1182/blood-2011-05-354449
10.1016/j.ccell.2017.08.003
10.1182/blood-2012-06-438002
10.1126/sciimmunol.abd4344
10.1038/nbt.1754
10.1101/gad.477908
10.1016/j.ymthe.2017.05.012
10.1172/JCI84813
10.1002/gcc.22996
10.1016/j.celrep.2021.110047
10.1016/j.ccell.2019.01.002
10.1002/(SICI)1096-911X(199902)32:2<88::AID-MPO3>3.0.CO;2-N
10.1038/s41467-020-17175-8
10.1158/2326-6066.CIR-14-0192
ContentType Journal Article
Copyright 2023
Published by Elsevier Inc.
Copyright_xml – notice: 2023
– notice: Published by Elsevier Inc.
DBID 6I.
AAFTH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1016/j.xcrm.2023.101212
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2666-3791
EndPage 101212
ExternalDocumentID PMC10591056
37774704
10_1016_j_xcrm_2023_101212
S2666379123003798
1_s2_0_S2666379123003798
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Intramural
GroupedDBID .1-
.FO
0R~
53G
AAEDW
AALRI
AAMRU
AAXUO
AAYWO
ACVFH
ADCNI
ADVLN
AEUPX
AFPUW
AFRHN
AIGII
AITUG
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
APXCP
EBS
FDB
GROUPED_DOAJ
M41
M~E
OK1
ROL
RPM
Z5R
AAHOK
NCXOZ
0SF
6I.
AAFTH
ACHIH
AFCTW
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c562t-31bb201a59a39fb6b67cede4230d4939dad9de49dbf4d81a27c9e5da98911dd33
ISSN 2666-3791
IngestDate Thu Aug 21 18:35:57 EDT 2025
Fri Jul 11 16:41:25 EDT 2025
Wed Feb 19 02:04:06 EST 2025
Thu Apr 24 23:04:49 EDT 2025
Tue Jul 01 01:25:25 EDT 2025
Sat May 11 15:33:27 EDT 2024
Tue Feb 25 19:56:01 EST 2025
Tue Aug 26 19:32:44 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 10
Keywords specific cytotoxicity
rhabdomyosarcoma
FGFR4
CAR T cell therapy
Language English
License This is an open access article under the CC BY-NC-ND license.
Published by Elsevier Inc.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c562t-31bb201a59a39fb6b67cede4230d4939dad9de49dbf4d81a27c9e5da98911dd33
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally
Lead contact
ORCID 0000-0002-5858-0488
OpenAccessLink http://dx.doi.org/10.1016/j.xcrm.2023.101212
PMID 37774704
PQID 2870992277
PQPubID 23479
PageCount 1
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_10591056
proquest_miscellaneous_2870992277
pubmed_primary_37774704
crossref_citationtrail_10_1016_j_xcrm_2023_101212
crossref_primary_10_1016_j_xcrm_2023_101212
elsevier_sciencedirect_doi_10_1016_j_xcrm_2023_101212
elsevier_clinicalkeyesjournals_1_s2_0_S2666379123003798
elsevier_clinicalkey_doi_10_1016_j_xcrm_2023_101212
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-10-17
PublicationDateYYYYMMDD 2023-10-17
PublicationDate_xml – month: 10
  year: 2023
  text: 2023-10-17
  day: 17
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Cell reports. Medicine
PublicationTitleAlternate Cell Rep Med
PublicationYear 2023
Publisher Elsevier Inc
Elsevier
Publisher_xml – name: Elsevier Inc
– name: Elsevier
References Crose, Etheridge, Chen, Belyea, Talbot, Bentley, Linardic (bib8) 2012; 18
Kasamon, Price, Okusanya, Richardson, Li, Ma, Wu, Theoret, Pazdur, Gormley (bib22) 2021; 26
Shukla, Ameur, Yilmaz, Nafa, Lau, Marchetti, Borsu, Barr, Ladanyi (bib33) 2012; 18
Bisogno, Ferrari, Prete, Messina, Basso, Cecchetto, Indolfi, Scarzello, D'Angelo, De Sio (bib38) 2009; 45
Kuroda, Kutner, Bazan, Reiser (bib60) 2009; 157
Mascarenhas, Chi, Hingorani, Anderson, Lyden, Rodeberg, Indelicato, Kao, Dasgupta, Spunt (bib42) 2019; 37
Robinson, Thorvaldsdóttir, Winckler, Guttman, Lander, Getz, Mesirov (bib59) 2011; 29
Gryder, Yohe, Chou, Zhang, Marques, Wachtel, Schaefer, Sen, Song, Gualtieri (bib6) 2017; 7
Haso, Lee, Shah, Stetler-Stevenson, Yuan, Pastan, Dimitrov, Morgan, FitzGerald, Barrett (bib21) 2013; 121
Alijaj, Moutel, Gouveia, Gray, Roveri, Dzhumashev, Weber, Meier, Luciani, Rössler (bib30) 2020; 12
Taylor, Cheuk, Tsang, Chung, Song, Desai, Yu, Chen, Shah, Youngblood (bib9) 2009; 119
Skapek, Ferrari, Gupta, Lupo, Butler, Shipley, Barr, Hawkins (bib1) 2019; 5
Zhao, Caretti, Mitchell, McKeehan, Boskey, Pachman, Sartorelli, Hoffman (bib13) 2006; 281
Sharma, Kanapuru, George, Lin, Xu, Bryan, Pazdur, Theoret (bib24) 2022; 28
Louis, Savoldo, Dotti, Pule, Yvon, Myers, Rossig, Russell, Diouf, Liu (bib46) 2011; 118
Straathof, Flutter, Wallace, Jain, Loka, Depani, Wright, Thomas, Cheung, Gileadi (bib26) 2020; 12
Bouchkouj, Zimmerman, Kasamon, Wang, Dai, Xu, Wang, Theoret, Purohit-Sheth, George (bib20) 2022
Bouchkouj, Kasamon, de Claro, George, Lin, Lee, Blumenthal, Bryan, McKee, Pazdur (bib19) 2019; 25
Mitra, Sydow, Magnusson, Piccinelli, Törnudd, Øra, Ljungman, Sandgren, Gisselsson, Mertens (bib29) 2022; 61
Walker, Majzner, Zhang, Wanhainen, Long, Nguyen, Lopomo, Vigny, Fry, Orentas, Mackall (bib47) 2017; 25
Li, Fu, Hewitt, Dimitrov, Ho (bib49) 2017; 114
Gryder, Wachtel, Chang, El Demerdash, Aboreden, Mohammed, Ewert, Pomella, Rota, Wei (bib5) 2020; 23
Majzner, Rietberg, Sotillo, Dong, Vachharajani, Labanieh, Myklebust, Kadapakkam, Weber, Tousley (bib35) 2020; 10
Majzner, Heitzeneder, Mackall (bib17) 2017; 31
Navai, Derenzo, Joseph, Sanber, Byrd, Zhang, Mata, Gerken, Shree, Mathew (bib55) 2019
Heitzeneder, Bosse, Zhu, Zhelev, Majzner, Radosevich, Dhingra, Sotillo, Buongervino, Pascual-Pasto (bib34) 2022; 40
Lagha, Kormish, Rocancourt, Manceau, Epstein, Zaret, Relaix, Buckingham (bib12) 2008; 22
Walterhouse, Hoover, Marymont, Kletzel (bib41) 1999; 32
Grupp, Kalos, Barrett, Aplenc, Porter, Rheingold, Teachey, Chew, Hauck, Wright (bib16) 2013; 368
Bosse, Raman, Zhu, Lane, Martinez, Heitzeneder, Rathi, Kendsersky, Randall, Donovan (bib48) 2017; 32
Majzner, Ramakrishna, Yeom, Patel, Chinnasamy, Schultz, Richards, Jiang, Barsan, Mancusi (bib27) 2022; 603
Weigel, Breitfeld, Hawkins, Crist, Baker (bib40) 2001; 23
Odeniyide, Yohe, Pollard, Vaseva, Calizo, Zhang, Rodriguez, Gross, Allen, Wan (bib44) 2022; 41
Chen, Stewart, Shelat, Qu, Bahrami, Hatley, Wu, Bradley, McEvoy, Pappo (bib14) 2013; 24
Yohe, Gryder, Shern, Song, Chou, Sindiri, Mendoza, Patidar, Zhang, Guha (bib43) 2018; 10
O'Leary, Lu, Huang, Lin, Mahmood, Przepiorka, Gavin, Lee, Liu, George (bib23) 2019; 25
Boulch, Cazaux, Loe-Mie, Thibaut, Corre, Lemaître, Grandjean, Garcia, Bousso (bib36) 2021; 6
Khan, Wei, Ringnér, Saal, Ladanyi, Westermann, Berthold, Schwab, Antonescu, Peterson, Meltzer (bib10) 2001; 7
Johnson, Scholler, Ohkuri, Kosaka, Patel, McGettigan, Nace, Dentchev, Thekkat, Loew (bib52) 2015; 7
Morello, Sadelain, Adusumilli (bib50) 2016; 6
Du, Hirabayashi, Ahn, Kren, Montgomery, Wang, Tiruthani, Mirlekar, Michaud, Greene (bib53) 2019; 35
Hegde, Joseph, Pashankar, DeRenzo, Sanber, Navai, Byrd, Hicks, Xu, Gerken (bib28) 2020; 11
Shern, Yohe, Khan (bib3) 2015; 20
Sullivan, Kumar, Li, Hoglund, Wang, Zhang, Shi, Beak, Cheuk, Jensen (bib31) 2022; 21
Tian, Cheuk, Wei, Abdelmaksoud, Chou, Milewski, Kelly, Song, Dower, Li (bib61) 2022; 132
Sadelain, Brentjens, Rivière (bib18) 2013; 3
Brohl, Sindiri, Wei, Milewski, Chou, Song, Wen, Kumar, Reardon, Mudunuri (bib32) 2021; 37
Shern, Chen, Chmielecki, Wei, Patidar, Rosenberg, Ambrogio, Auclair, Wang, Song (bib2) 2014; 4
Heczey, Louis, Savoldo, Dakhova, Durett, Grilley, Liu, Wu, Mei, Gee (bib25) 2017; 25
Zhao, Hoffman (bib11) 2004; 229
Khan, Bittner, Saal, Teichmann, Azorsa, Gooden, Pavan, Trent, Meltzer (bib4) 1999; 96
Paszkiewicz, Fräßle, Srivastava, Sommermeyer, Hudecek, Drexler, Sadelain, Liu, Jensen, Riddell, Busch (bib56) 2016; 126
Weigel, Lyden, Anderson, Meyer, Parham, Rodeberg, Michalski, Hawkins, Arndt (bib7) 2016; 34
Majzner, Theruvath, Nellan, Heitzeneder, Cui, Mount, Rietberg, Linde, Xu, Rota (bib54) 2019; 25
Santoro, Kim, Motz, Alatzoglou, Li, Irving, Powell, Coukos (bib45) 2015; 3
Sun, Shi, Liu, Liu, Liu, Sun (bib51) 2014; 16
Gryder, Pomella, Sayers, Wu, Song, Chiarella, Bagchi, Chou, Sinniah, Walton (bib58) 2019; 51
Lee, Kochenderfer, Stetler-Stevenson, Cui, Delbrook, Feldman, Fry, Orentas, Sabatino, Shah (bib15) 2015; 385
Chang, Brohl, Patidar, Sindiri, Shern, Wei, Song, Yohe, Gryder, Zhang (bib57) 2016; 22
Oberlin, Rey, Lyden, Bisogno, Stevens, Meyer, Carli, Anderson (bib39) 2008; 26
June, O'Connor, Kawalekar, Ghassemi, Milone (bib37) 2018; 359
Majzner (10.1016/j.xcrm.2023.101212_bib27) 2022; 603
Oberlin (10.1016/j.xcrm.2023.101212_bib39) 2008; 26
Majzner (10.1016/j.xcrm.2023.101212_bib17) 2017; 31
Louis (10.1016/j.xcrm.2023.101212_bib46) 2011; 118
Morello (10.1016/j.xcrm.2023.101212_bib50) 2016; 6
Gryder (10.1016/j.xcrm.2023.101212_bib58) 2019; 51
Heczey (10.1016/j.xcrm.2023.101212_bib25) 2017; 25
Heitzeneder (10.1016/j.xcrm.2023.101212_bib34) 2022; 40
Walker (10.1016/j.xcrm.2023.101212_bib47) 2017; 25
Grupp (10.1016/j.xcrm.2023.101212_bib16) 2013; 368
Kasamon (10.1016/j.xcrm.2023.101212_bib22) 2021; 26
Taylor (10.1016/j.xcrm.2023.101212_bib9) 2009; 119
Crose (10.1016/j.xcrm.2023.101212_bib8) 2012; 18
Gryder (10.1016/j.xcrm.2023.101212_bib6) 2017; 7
Majzner (10.1016/j.xcrm.2023.101212_bib54) 2019; 25
Chen (10.1016/j.xcrm.2023.101212_bib14) 2013; 24
Shukla (10.1016/j.xcrm.2023.101212_bib33) 2012; 18
Lagha (10.1016/j.xcrm.2023.101212_bib12) 2008; 22
Shern (10.1016/j.xcrm.2023.101212_bib3) 2015; 20
Haso (10.1016/j.xcrm.2023.101212_bib21) 2013; 121
Paszkiewicz (10.1016/j.xcrm.2023.101212_bib56) 2016; 126
Yohe (10.1016/j.xcrm.2023.101212_bib43) 2018; 10
Johnson (10.1016/j.xcrm.2023.101212_bib52) 2015; 7
Weigel (10.1016/j.xcrm.2023.101212_bib7) 2016; 34
Majzner (10.1016/j.xcrm.2023.101212_bib35) 2020; 10
Mascarenhas (10.1016/j.xcrm.2023.101212_bib42) 2019; 37
Sullivan (10.1016/j.xcrm.2023.101212_bib31) 2022; 21
Li (10.1016/j.xcrm.2023.101212_bib49) 2017; 114
Sharma (10.1016/j.xcrm.2023.101212_bib24) 2022; 28
Sun (10.1016/j.xcrm.2023.101212_bib51) 2014; 16
Chang (10.1016/j.xcrm.2023.101212_bib57) 2016; 22
O'Leary (10.1016/j.xcrm.2023.101212_bib23) 2019; 25
Gryder (10.1016/j.xcrm.2023.101212_bib5) 2020; 23
Kuroda (10.1016/j.xcrm.2023.101212_bib60) 2009; 157
Santoro (10.1016/j.xcrm.2023.101212_bib45) 2015; 3
Lee (10.1016/j.xcrm.2023.101212_bib15) 2015; 385
Sadelain (10.1016/j.xcrm.2023.101212_bib18) 2013; 3
June (10.1016/j.xcrm.2023.101212_bib37) 2018; 359
Khan (10.1016/j.xcrm.2023.101212_bib10) 2001; 7
Khan (10.1016/j.xcrm.2023.101212_bib4) 1999; 96
Bisogno (10.1016/j.xcrm.2023.101212_bib38) 2009; 45
Tian (10.1016/j.xcrm.2023.101212_bib61) 2022; 132
Bouchkouj (10.1016/j.xcrm.2023.101212_bib19) 2019; 25
Robinson (10.1016/j.xcrm.2023.101212_bib59) 2011; 29
Weigel (10.1016/j.xcrm.2023.101212_bib40) 2001; 23
Alijaj (10.1016/j.xcrm.2023.101212_bib30) 2020; 12
Mitra (10.1016/j.xcrm.2023.101212_bib29) 2022; 61
Bosse (10.1016/j.xcrm.2023.101212_bib48) 2017; 32
Shern (10.1016/j.xcrm.2023.101212_bib2) 2014; 4
Navai (10.1016/j.xcrm.2023.101212_bib55) 2019
Bouchkouj (10.1016/j.xcrm.2023.101212_bib20) 2022
Zhao (10.1016/j.xcrm.2023.101212_bib13) 2006; 281
Skapek (10.1016/j.xcrm.2023.101212_bib1) 2019; 5
Boulch (10.1016/j.xcrm.2023.101212_bib36) 2021; 6
Du (10.1016/j.xcrm.2023.101212_bib53) 2019; 35
Zhao (10.1016/j.xcrm.2023.101212_bib11) 2004; 229
Hegde (10.1016/j.xcrm.2023.101212_bib28) 2020; 11
Brohl (10.1016/j.xcrm.2023.101212_bib32) 2021; 37
Walterhouse (10.1016/j.xcrm.2023.101212_bib41) 1999; 32
Straathof (10.1016/j.xcrm.2023.101212_bib26) 2020; 12
Odeniyide (10.1016/j.xcrm.2023.101212_bib44) 2022; 41
38723625 - Cell Rep Med. 2024 May 8;:101586
References_xml – volume: 37
  start-page: 2866
  year: 2019
  end-page: 2874
  ident: bib42
  article-title: Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children's Oncology Group
  publication-title: J. Clin. Oncol.
– volume: 18
  start-page: 3780
  year: 2012
  end-page: 3790
  ident: bib8
  article-title: FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma
  publication-title: Clin. Cancer Res.
– volume: 37
  year: 2021
  ident: bib32
  article-title: Immuno-transcriptomic profiling of extracranial pediatric solid malignancies
  publication-title: Cell Rep.
– volume: 126
  start-page: 4262
  year: 2016
  end-page: 4272
  ident: bib56
  article-title: Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia
  publication-title: J. Clin. Invest.
– volume: 34
  start-page: 117
  year: 2016
  end-page: 122
  ident: bib7
  article-title: Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group
  publication-title: J. Clin. Oncol.
– volume: 132
  year: 2022
  ident: bib61
  article-title: An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma
  publication-title: J. Clin. Invest.
– volume: 18
  start-page: 748
  year: 2012
  end-page: 757
  ident: bib33
  article-title: Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways
  publication-title: Clin. Cancer Res.
– volume: 157
  start-page: 113
  year: 2009
  end-page: 121
  ident: bib60
  article-title: Simplified lentivirus vector production in protein-free media using polyethylenimine-mediated transfection
  publication-title: J. Virol. Methods
– volume: 10
  start-page: 702
  year: 2020
  end-page: 723
  ident: bib35
  article-title: Tuning the Antigen Density Requirement for CAR T-cell Activity
  publication-title: Cancer Discov.
– volume: 51
  start-page: 1714
  year: 2019
  end-page: 1722
  ident: bib58
  article-title: Histone hyperacetylation disrupts core gene regulatory architecture in rhabdomyosarcoma
  publication-title: Nat. Genet.
– volume: 26
  start-page: 2384
  year: 2008
  end-page: 2389
  ident: bib39
  article-title: Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups
  publication-title: J. Clin. Oncol.
– volume: 119
  start-page: 3395
  year: 2009
  end-page: 3407
  ident: bib9
  article-title: Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models
  publication-title: J. Clin. Invest.
– volume: 23
  year: 2020
  ident: bib5
  article-title: Miswired Enhancer Logic Drives a Cancer of the Muscle Lineage
  publication-title: iScience
– volume: 22
  start-page: 1828
  year: 2008
  end-page: 1837
  ident: bib12
  article-title: Pax3 regulation of FGF signaling affects the progression of embryonic progenitor cells into the myogenic program
  publication-title: Genes Dev.
– year: 2022
  ident: bib20
  article-title: FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma
  publication-title: Oncol.
– volume: 26
  start-page: 879
  year: 2021
  end-page: 886
  ident: bib22
  article-title: FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
  publication-title: Oncol.
– volume: 6
  year: 2021
  ident: bib36
  article-title: A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity
  publication-title: Sci. Immunol.
– volume: 3
  start-page: 388
  year: 2013
  end-page: 398
  ident: bib18
  article-title: The basic principles of chimeric antigen receptor design
  publication-title: Cancer Discov.
– volume: 12
  year: 2020
  ident: bib26
  article-title: Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma
  publication-title: Sci. Transl. Med.
– volume: 25
  start-page: 2214
  year: 2017
  end-page: 2224
  ident: bib25
  article-title: CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma
  publication-title: Mol. Ther.
– year: 2019
  ident: bib55
  article-title: Administration of HER2-CAR T cells after lymphodepletion safely improves T cell expansion and induces clinical responses in patients with advanced sarcomas
  publication-title: Proceedings of the 110th Annual Meeting of the American Association for Cancer Research
– volume: 25
  start-page: 1702
  year: 2019
  end-page: 1708
  ident: bib19
  article-title: FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma
  publication-title: Clin. Cancer Res.
– volume: 7
  start-page: 673
  year: 2001
  end-page: 679
  ident: bib10
  article-title: Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks
  publication-title: Nat. Med.
– volume: 3
  start-page: 68
  year: 2015
  end-page: 84
  ident: bib45
  article-title: T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression
  publication-title: Cancer Immunol. Res.
– volume: 6
  start-page: 133
  year: 2016
  end-page: 146
  ident: bib50
  article-title: Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors
  publication-title: Cancer Discov.
– volume: 21
  start-page: 1608
  year: 2022
  end-page: 1621
  ident: bib31
  article-title: FGFR4-targeted chimeric antigen receptors (CARs) combined with anti-myeloid poly-pharmacy effectively treats orthotopic rhabdomyosarcoma
  publication-title: Mol. Cancer Therapeut.
– volume: 28
  start-page: 1759
  year: 2022
  end-page: 1764
  ident: bib24
  article-title: FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma
  publication-title: Clin. Cancer Res.
– volume: 12
  year: 2020
  ident: bib30
  article-title: Novel FGFR4-Targeting Single-Domain Antibodies for Multiple Targeted Therapies against Rhabdomyosarcoma
  publication-title: Cancers
– volume: 61
  start-page: 5
  year: 2022
  end-page: 9
  ident: bib29
  article-title: Amplification of ERBB2 (HER2) in embryonal rhabdomyosarcoma: A potential treatment target in rare cases?
  publication-title: Genes Chromosomes Cancer
– volume: 359
  start-page: 1361
  year: 2018
  end-page: 1365
  ident: bib37
  article-title: CAR T cell immunotherapy for human cancer
  publication-title: Science
– volume: 114
  start-page: E6623
  year: 2017
  end-page: E6631
  ident: bib49
  article-title: Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma
  publication-title: Proc. Natl. Acad. Sci. USA
– volume: 31
  start-page: 476
  year: 2017
  end-page: 485
  ident: bib17
  article-title: Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers
  publication-title: Cancer Cell
– volume: 24
  start-page: 710
  year: 2013
  end-page: 724
  ident: bib14
  article-title: Targeting oxidative stress in embryonal rhabdomyosarcoma
  publication-title: Cancer Cell
– volume: 23
  start-page: 272
  year: 2001
  end-page: 276
  ident: bib40
  article-title: Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma
  publication-title: J. Pediatr. Hematol. Oncol.
– volume: 10
  year: 2018
  ident: bib43
  article-title: MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma
  publication-title: Sci. Transl. Med.
– volume: 368
  start-page: 1509
  year: 2013
  end-page: 1518
  ident: bib16
  article-title: Chimeric antigen receptor-modified T cells for acute lymphoid leukemia
  publication-title: N. Engl. J. Med.
– volume: 385
  start-page: 517
  year: 2015
  end-page: 528
  ident: bib15
  article-title: T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
  publication-title: Lancet
– volume: 121
  start-page: 1165
  year: 2013
  end-page: 1174
  ident: bib21
  article-title: Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
  publication-title: Blood
– volume: 118
  start-page: 6050
  year: 2011
  end-page: 6056
  ident: bib46
  article-title: Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
  publication-title: Blood
– volume: 4
  start-page: 216
  year: 2014
  end-page: 231
  ident: bib2
  article-title: Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors
  publication-title: Cancer Discov.
– volume: 7
  start-page: 884
  year: 2017
  end-page: 899
  ident: bib6
  article-title: PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability
  publication-title: Cancer Discov.
– volume: 25
  start-page: 1142
  year: 2019
  end-page: 1146
  ident: bib23
  article-title: FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia
  publication-title: Clin. Cancer Res.
– volume: 603
  start-page: 934
  year: 2022
  end-page: 941
  ident: bib27
  article-title: GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
  publication-title: Nature
– volume: 16
  start-page: R61
  year: 2014
  ident: bib51
  article-title: Construction and evaluation of a novel humanized HER2-specific chimeric receptor
  publication-title: Breast Cancer Res.
– volume: 25
  start-page: 2189
  year: 2017
  end-page: 2201
  ident: bib47
  article-title: Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase
  publication-title: Mol. Ther.
– volume: 5
  start-page: 1
  year: 2019
  ident: bib1
  article-title: Rhabdomyosarcoma
  publication-title: Nat. Rev. Dis. Prim.
– volume: 32
  start-page: 88
  year: 1999
  end-page: 92
  ident: bib41
  article-title: High-dose chemotherapy followed by peripheral blood stem cell rescue for metastatic rhabdomyosarcoma: the experience at Chicago Children's Memorial Hospital
  publication-title: Med. Pediatr. Oncol.
– volume: 40
  start-page: 53
  year: 2022
  end-page: 69.e9
  ident: bib34
  article-title: GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity
  publication-title: Cancer Cell
– volume: 45
  start-page: 3035
  year: 2009
  end-page: 3041
  ident: bib38
  article-title: Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcoma
  publication-title: Eur. J. Cancer
– volume: 229
  start-page: 380
  year: 2004
  end-page: 392
  ident: bib11
  article-title: Embryonic myogenesis pathways in muscle regeneration
  publication-title: Dev. Dynam.
– volume: 20
  start-page: 227
  year: 2015
  end-page: 243
  ident: bib3
  article-title: Pediatric Rhabdomyosarcoma
  publication-title: Crit. Rev. Oncog.
– volume: 25
  start-page: 2560
  year: 2019
  end-page: 2574
  ident: bib54
  article-title: CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors
  publication-title: Clin. Cancer Res.
– volume: 96
  start-page: 13264
  year: 1999
  end-page: 13269
  ident: bib4
  article-title: cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene
  publication-title: Proc. Natl. Acad. Sci. USA
– volume: 35
  start-page: 221
  year: 2019
  end-page: 237.e8
  ident: bib53
  article-title: Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells
  publication-title: Cancer Cell
– volume: 11
  start-page: 3549
  year: 2020
  ident: bib28
  article-title: Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma
  publication-title: Nat. Commun.
– volume: 7
  start-page: 275ra22
  year: 2015
  ident: bib52
  article-title: Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma
  publication-title: Sci. Transl. Med.
– volume: 32
  start-page: 295
  year: 2017
  end-page: 309.e12
  ident: bib48
  article-title: Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma
  publication-title: Cancer Cell
– volume: 29
  start-page: 24
  year: 2011
  end-page: 26
  ident: bib59
  article-title: Integrative genomics viewer
  publication-title: Nat. Biotechnol.
– volume: 41
  start-page: 3037
  year: 2022
  ident: bib44
  article-title: Correction: Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma
  publication-title: Oncogene
– volume: 281
  start-page: 429
  year: 2006
  end-page: 438
  ident: bib13
  article-title: Fgfr4 is required for effective muscle regeneration in vivo. Delineation of a MyoD-Tead2-Fgfr4 transcriptional pathway
  publication-title: J. Biol. Chem.
– volume: 22
  start-page: 3810
  year: 2016
  end-page: 3820
  ident: bib57
  article-title: MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research
  publication-title: Clin. Cancer Res.
– volume: 20
  start-page: 227
  year: 2015
  ident: 10.1016/j.xcrm.2023.101212_bib3
  article-title: Pediatric Rhabdomyosarcoma
  publication-title: Crit. Rev. Oncog.
  doi: 10.1615/CritRevOncog.2015013800
– volume: 18
  start-page: 3780
  year: 2012
  ident: 10.1016/j.xcrm.2023.101212_bib8
  article-title: FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-10-3063
– volume: 26
  start-page: 879
  year: 2021
  ident: 10.1016/j.xcrm.2023.101212_bib22
  article-title: FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
  publication-title: Oncol.
  doi: 10.1002/onco.13859
– volume: 385
  start-page: 517
  year: 2015
  ident: 10.1016/j.xcrm.2023.101212_bib15
  article-title: T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(14)61403-3
– volume: 119
  start-page: 3395
  year: 2009
  ident: 10.1016/j.xcrm.2023.101212_bib9
  article-title: Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models
  publication-title: J. Clin. Invest.
– volume: 6
  start-page: 133
  year: 2016
  ident: 10.1016/j.xcrm.2023.101212_bib50
  article-title: Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-15-0583
– volume: 26
  start-page: 2384
  year: 2008
  ident: 10.1016/j.xcrm.2023.101212_bib39
  article-title: Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2007.14.7207
– volume: 603
  start-page: 934
  year: 2022
  ident: 10.1016/j.xcrm.2023.101212_bib27
  article-title: GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
  publication-title: Nature
  doi: 10.1038/s41586-022-04489-4
– volume: 25
  start-page: 1702
  year: 2019
  ident: 10.1016/j.xcrm.2023.101212_bib19
  article-title: FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-18-2743
– volume: 281
  start-page: 429
  year: 2006
  ident: 10.1016/j.xcrm.2023.101212_bib13
  article-title: Fgfr4 is required for effective muscle regeneration in vivo. Delineation of a MyoD-Tead2-Fgfr4 transcriptional pathway
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M507440200
– volume: 31
  start-page: 476
  year: 2017
  ident: 10.1016/j.xcrm.2023.101212_bib17
  article-title: Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2017.03.002
– year: 2022
  ident: 10.1016/j.xcrm.2023.101212_bib20
  article-title: FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma
  publication-title: Oncol.
– volume: 359
  start-page: 1361
  year: 2018
  ident: 10.1016/j.xcrm.2023.101212_bib37
  article-title: CAR T cell immunotherapy for human cancer
  publication-title: Science
  doi: 10.1126/science.aar6711
– volume: 45
  start-page: 3035
  year: 2009
  ident: 10.1016/j.xcrm.2023.101212_bib38
  article-title: Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcoma
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2009.08.019
– volume: 23
  start-page: 272
  year: 2001
  ident: 10.1016/j.xcrm.2023.101212_bib40
  article-title: Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma
  publication-title: J. Pediatr. Hematol. Oncol.
  doi: 10.1097/00043426-200106000-00007
– volume: 41
  start-page: 3037
  year: 2022
  ident: 10.1016/j.xcrm.2023.101212_bib44
  article-title: Correction: Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma
  publication-title: Oncogene
  doi: 10.1038/s41388-022-02342-6
– volume: 368
  start-page: 1509
  year: 2013
  ident: 10.1016/j.xcrm.2023.101212_bib16
  article-title: Chimeric antigen receptor-modified T cells for acute lymphoid leukemia
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1215134
– volume: 23
  year: 2020
  ident: 10.1016/j.xcrm.2023.101212_bib5
  article-title: Miswired Enhancer Logic Drives a Cancer of the Muscle Lineage
  publication-title: iScience
  doi: 10.1016/j.isci.2020.101103
– volume: 5
  start-page: 1
  year: 2019
  ident: 10.1016/j.xcrm.2023.101212_bib1
  article-title: Rhabdomyosarcoma
  publication-title: Nat. Rev. Dis. Prim.
  doi: 10.1038/s41572-018-0051-2
– volume: 37
  start-page: 2866
  year: 2019
  ident: 10.1016/j.xcrm.2023.101212_bib42
  article-title: Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children's Oncology Group
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.19.00576
– volume: 21
  start-page: 1608
  year: 2022
  ident: 10.1016/j.xcrm.2023.101212_bib31
  article-title: FGFR4-targeted chimeric antigen receptors (CARs) combined with anti-myeloid poly-pharmacy effectively treats orthotopic rhabdomyosarcoma
  publication-title: Mol. Cancer Therapeut.
  doi: 10.1158/1535-7163.MCT-22-0059
– volume: 229
  start-page: 380
  year: 2004
  ident: 10.1016/j.xcrm.2023.101212_bib11
  article-title: Embryonic myogenesis pathways in muscle regeneration
  publication-title: Dev. Dynam.
  doi: 10.1002/dvdy.10457
– volume: 7
  start-page: 884
  year: 2017
  ident: 10.1016/j.xcrm.2023.101212_bib6
  article-title: PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-16-1297
– volume: 28
  start-page: 1759
  year: 2022
  ident: 10.1016/j.xcrm.2023.101212_bib24
  article-title: FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-21-3803
– volume: 7
  start-page: 673
  year: 2001
  ident: 10.1016/j.xcrm.2023.101212_bib10
  article-title: Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks
  publication-title: Nat. Med.
  doi: 10.1038/89044
– volume: 25
  start-page: 2560
  year: 2019
  ident: 10.1016/j.xcrm.2023.101212_bib54
  article-title: CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-18-0432
– volume: 22
  start-page: 3810
  year: 2016
  ident: 10.1016/j.xcrm.2023.101212_bib57
  article-title: MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-15-2717
– volume: 10
  year: 2018
  ident: 10.1016/j.xcrm.2023.101212_bib43
  article-title: MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.aan4470
– volume: 3
  start-page: 388
  year: 2013
  ident: 10.1016/j.xcrm.2023.101212_bib18
  article-title: The basic principles of chimeric antigen receptor design
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-12-0548
– volume: 40
  start-page: 53
  year: 2022
  ident: 10.1016/j.xcrm.2023.101212_bib34
  article-title: GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2021.12.005
– volume: 34
  start-page: 117
  year: 2016
  ident: 10.1016/j.xcrm.2023.101212_bib7
  article-title: Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2015.63.4048
– volume: 10
  start-page: 702
  year: 2020
  ident: 10.1016/j.xcrm.2023.101212_bib35
  article-title: Tuning the Antigen Density Requirement for CAR T-cell Activity
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-19-0945
– volume: 114
  start-page: E6623
  year: 2017
  ident: 10.1016/j.xcrm.2023.101212_bib49
  article-title: Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma
  publication-title: Proc. Natl. Acad. Sci. USA
– volume: 24
  start-page: 710
  year: 2013
  ident: 10.1016/j.xcrm.2023.101212_bib14
  article-title: Targeting oxidative stress in embryonal rhabdomyosarcoma
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2013.11.002
– volume: 7
  start-page: 275ra22
  year: 2015
  ident: 10.1016/j.xcrm.2023.101212_bib52
  article-title: Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.aaa4963
– volume: 51
  start-page: 1714
  year: 2019
  ident: 10.1016/j.xcrm.2023.101212_bib58
  article-title: Histone hyperacetylation disrupts core gene regulatory architecture in rhabdomyosarcoma
  publication-title: Nat. Genet.
  doi: 10.1038/s41588-019-0534-4
– volume: 12
  year: 2020
  ident: 10.1016/j.xcrm.2023.101212_bib26
  article-title: Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.abd6169
– volume: 12
  year: 2020
  ident: 10.1016/j.xcrm.2023.101212_bib30
  article-title: Novel FGFR4-Targeting Single-Domain Antibodies for Multiple Targeted Therapies against Rhabdomyosarcoma
  publication-title: Cancers
  doi: 10.3390/cancers12113313
– volume: 16
  start-page: R61
  year: 2014
  ident: 10.1016/j.xcrm.2023.101212_bib51
  article-title: Construction and evaluation of a novel humanized HER2-specific chimeric receptor
  publication-title: Breast Cancer Res.
  doi: 10.1186/bcr3674
– volume: 18
  start-page: 748
  year: 2012
  ident: 10.1016/j.xcrm.2023.101212_bib33
  article-title: Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-11-2056
– volume: 96
  start-page: 13264
  year: 1999
  ident: 10.1016/j.xcrm.2023.101212_bib4
  article-title: cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.96.23.13264
– year: 2019
  ident: 10.1016/j.xcrm.2023.101212_bib55
  article-title: Administration of HER2-CAR T cells after lymphodepletion safely improves T cell expansion and induces clinical responses in patients with advanced sarcomas
– volume: 157
  start-page: 113
  year: 2009
  ident: 10.1016/j.xcrm.2023.101212_bib60
  article-title: Simplified lentivirus vector production in protein-free media using polyethylenimine-mediated transfection
  publication-title: J. Virol. Methods
  doi: 10.1016/j.jviromet.2008.11.021
– volume: 132
  year: 2022
  ident: 10.1016/j.xcrm.2023.101212_bib61
  article-title: An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI155621
– volume: 25
  start-page: 1142
  year: 2019
  ident: 10.1016/j.xcrm.2023.101212_bib23
  article-title: FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-18-2035
– volume: 4
  start-page: 216
  year: 2014
  ident: 10.1016/j.xcrm.2023.101212_bib2
  article-title: Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-13-0639
– volume: 25
  start-page: 2189
  year: 2017
  ident: 10.1016/j.xcrm.2023.101212_bib47
  article-title: Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase
  publication-title: Mol. Ther.
  doi: 10.1016/j.ymthe.2017.06.008
– volume: 118
  start-page: 6050
  year: 2011
  ident: 10.1016/j.xcrm.2023.101212_bib46
  article-title: Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
  publication-title: Blood
  doi: 10.1182/blood-2011-05-354449
– volume: 32
  start-page: 295
  year: 2017
  ident: 10.1016/j.xcrm.2023.101212_bib48
  article-title: Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2017.08.003
– volume: 121
  start-page: 1165
  year: 2013
  ident: 10.1016/j.xcrm.2023.101212_bib21
  article-title: Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
  publication-title: Blood
  doi: 10.1182/blood-2012-06-438002
– volume: 6
  year: 2021
  ident: 10.1016/j.xcrm.2023.101212_bib36
  article-title: A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity
  publication-title: Sci. Immunol.
  doi: 10.1126/sciimmunol.abd4344
– volume: 29
  start-page: 24
  year: 2011
  ident: 10.1016/j.xcrm.2023.101212_bib59
  article-title: Integrative genomics viewer
  publication-title: Nat. Biotechnol.
  doi: 10.1038/nbt.1754
– volume: 22
  start-page: 1828
  year: 2008
  ident: 10.1016/j.xcrm.2023.101212_bib12
  article-title: Pax3 regulation of FGF signaling affects the progression of embryonic progenitor cells into the myogenic program
  publication-title: Genes Dev.
  doi: 10.1101/gad.477908
– volume: 25
  start-page: 2214
  year: 2017
  ident: 10.1016/j.xcrm.2023.101212_bib25
  article-title: CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma
  publication-title: Mol. Ther.
  doi: 10.1016/j.ymthe.2017.05.012
– volume: 126
  start-page: 4262
  year: 2016
  ident: 10.1016/j.xcrm.2023.101212_bib56
  article-title: Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI84813
– volume: 61
  start-page: 5
  year: 2022
  ident: 10.1016/j.xcrm.2023.101212_bib29
  article-title: Amplification of ERBB2 (HER2) in embryonal rhabdomyosarcoma: A potential treatment target in rare cases?
  publication-title: Genes Chromosomes Cancer
  doi: 10.1002/gcc.22996
– volume: 37
  year: 2021
  ident: 10.1016/j.xcrm.2023.101212_bib32
  article-title: Immuno-transcriptomic profiling of extracranial pediatric solid malignancies
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2021.110047
– volume: 35
  start-page: 221
  year: 2019
  ident: 10.1016/j.xcrm.2023.101212_bib53
  article-title: Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2019.01.002
– volume: 32
  start-page: 88
  year: 1999
  ident: 10.1016/j.xcrm.2023.101212_bib41
  article-title: High-dose chemotherapy followed by peripheral blood stem cell rescue for metastatic rhabdomyosarcoma: the experience at Chicago Children's Memorial Hospital
  publication-title: Med. Pediatr. Oncol.
  doi: 10.1002/(SICI)1096-911X(199902)32:2<88::AID-MPO3>3.0.CO;2-N
– volume: 11
  start-page: 3549
  year: 2020
  ident: 10.1016/j.xcrm.2023.101212_bib28
  article-title: Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-17175-8
– volume: 3
  start-page: 68
  year: 2015
  ident: 10.1016/j.xcrm.2023.101212_bib45
  article-title: T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-14-0192
– reference: 38723625 - Cell Rep Med. 2024 May 8;:101586
SSID ssj0002511830
Score 2.3164563
Snippet Pediatric patients with relapsed or refractory rhabdomyosarcoma (RMS) have dismal cure rates, and effective therapy is urgently needed. The oncogenic receptor...
SummaryPediatric patients with relapsed or refractory rhabdomyosarcoma (RMS) have dismal cure rates, and effective therapy is urgently needed. The oncogenic...
SourceID pubmedcentral
proquest
pubmed
crossref
elsevier
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 101212
SubjectTerms Advanced Basic Science
Animals
CAR T cell therapy
Cell Line, Tumor
Child
FGFR4
Humans
Immunotherapy, Adoptive
Mice
Receptor, Fibroblast Growth Factor, Type 4 - genetics
Receptor, Fibroblast Growth Factor, Type 4 - metabolism
Receptors, Chimeric Antigen - genetics
rhabdomyosarcoma
Rhabdomyosarcoma - drug therapy
specific cytotoxicity
Title Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma
URI https://www.clinicalkey.com/#!/content/1-s2.0-S2666379123003798
https://www.clinicalkey.es/playcontent/1-s2.0-S2666379123003798
https://dx.doi.org/10.1016/j.xcrm.2023.101212
https://www.ncbi.nlm.nih.gov/pubmed/37774704
https://www.proquest.com/docview/2870992277
https://pubmed.ncbi.nlm.nih.gov/PMC10591056
Volume 4
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9NAEF5BkRAviJtwVIvEW5TIzvp8RKihQm1A1JH6ttrLxFGxozhFwK9n9vCRNJTCQ5zE2Y2T_T7PzszOzCL0FuSiL3wegW0ik1EgYjYCrSgf-bnwWRKGKjVZ_Kez6HgefDwPz7vlApNdsuFj8WtvXsn_oArnAFedJfsPyLZfCifgNeALR0AYjjfC-DOIqyazUXbRPy7ncVHYOHkYO11ycwiN1QpM7GE21O76oU29Au3TBINrl8H0w_RLYDJcFozL6tvPqob7oHKiu6lnoPu6pYaxXejprc1nhfWonqpiWfTWfQqbAlJ2rtazRfGdrdastiSbgTnAamBWx7Ti6yJ31bbt5msuRcI5KSYm3M3mZFpZBmpABLLMbsw1VnvOOWEc9Dnn9SSrrkNmA66vCH3rf1iOf4i1ri0wIeOu8XaF7dknOp2fnNDs6Dy7je5MwLQgPQ-Pnr2NyWW2qGl_n8u1smGBuxf5kz5z1V7ZDbvt6THZA3TfGSD4nWXTQ3RLlY_Q3QbGx6jokQr3SIWrHDPckAo7UuGGVDjDmlTYkQq3pMKGVLiApjukeoLm06Ps_fHI7ccxEqAlb2C65hz0RRamjKQ5j3gUCyUVKOSeDFKSSiZTeJtKHfyZ-GwSi1SFkqUJzKhSEvIUHZRVqZ4jHMs8El7OQUUjgQp4QgLBSS4EjD3YINEA-c2oUuGK1es9Uy5oE5W4pBoJqpGgFokBGrZ9VrZUy7WtSQMWbUYVpk0KpLq2V7yvl6qdVKipT-sJ9eiZZo8mDwyOB8_JAIVtT6fcWqX1r1d80zCJguTXULJSVZc11SEKuqp0HA_QM8us9n-TGMy62AsGKNniXNtAV5Xf_qQsFqa6vDa44BG9uMGFX6J73d3-Ch1s1pfqNSjpG35onFuH5t76DeyE7Bc
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Preclinical+development+of+a+chimeric+antigen+receptor+T+cell+therapy+targeting+FGFR4+in+rhabdomyosarcoma&rft.jtitle=Cell+reports.+Medicine&rft.au=Tian%2C+Meijie&rft.au=Wei%2C+Jun+S&rft.au=Shivaprasad%2C+Nityashree&rft.au=Highfill%2C+Steven+L&rft.date=2023-10-17&rft.issn=2666-3791&rft.eissn=2666-3791&rft.volume=4&rft.issue=10&rft.spage=101212&rft_id=info:doi/10.1016%2Fj.xcrm.2023.101212&rft.externalDBID=NO_FULL_TEXT
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F26663791%2FS2666379122X00116%2Fcov150h.gif